Table 2 Patient characteristics in long-term CMR evaluation cohort (n = 47)
Characteristics | All participants (n = 47) | Participants with pair baseline and 12 weeks since start anthracycline LVEF evaluation by echocardiogram (n = 47#) | ||
|---|---|---|---|---|
LVEF decline ≥ 10% (n = 16) | No LVEF decline (n = 31) | p-value | ||
Median age at breast cancer diagnosis, (range) (y) | 46 (26–64) | 44 (31–53) | 49 (26–64) | 0.84 |
Baseline HFA-ICOS cardiovascular risk | ||||
 - Low (%)  - Moderate (%)  - High (%) | 42 (89.4) 5 (10.6) 0 | 14 2 0 | 28 3 0 | 0.35 |
BMI (kg/m2) at diagnosis | 24.0 ± 4.4 | 23.7 ± 4.1 | 24.2 ± 4.6 | 0.69 |
Cumulative doxorubicin-equivalent dose (mg/m2) | 225.5 ± 11.3 | 226 ± 11.5 | 224 ± 11.3 | 0.55 |
Baseline LVEF by echocardiogram (%) | 70.7 ± 6.7 | 75.2 ± 7.2 | 68.4 ± 5.2 | < 0.01* |
End-anthracycline LVEF by echocardiogram (%) | 66.3 ± 6.2 | 62.7 ± 6.5 | 68.1 ± 5.3 | < 0.01* |
Subsequent anti-HER2 therapy, n (%) | 9 (19.1) | 5 (31.2) | 4 (12.9) | 0.25 |
Left chest wall radiation, n (%) | 19 (40.4) | 7 (43.8) | 12 (38.7) | 0.36 |
Duration from baseline echocardiogram to CMR, (range) (y) | 12 (10–15) | 12 (11–14) | 12 (11–15) | 0.12 |
Age at time of CMR, (range) (y) | 59 (37–74) | 56 (44–66) | 61 (37–74) | 0.29 |